GHAPPcast: IBS-C Therapies Explained: Helping Patients Understand Their Options
GHAPPcast22 Okt 2025

GHAPPcast: IBS-C Therapies Explained: Helping Patients Understand Their Options

Thank you to Ardelyx for your support on this podcast episode.

In this podcast, Gabriella McCarty, NP, and Kimberly Orleck, PA-C, dive into the complexities of irritable bowel syndrome with constipation (IBS-C) and the wide range of therapies available to help patients. They discuss the importance of taking a thorough patient history to understand whether the primary symptom is constipation, bloating, abdominal pain, or overflow diarrhea—emphasizing that IBS-C treatment is not one-size-fits-all. Gabriella and Kim break down the differences between over-the-counter therapies like fiber and osmotic laxatives, which often help with bowel movements but do little for abdominal pain, and FDA-approved prescription options that also address visceral hypersensitivity, bloating, and global IBS symptoms. They explain how secretagogues and retenagogues work, set realistic expectations around therapy timelines, and highlight the importance of preparing patients for possible side effects such as diarrhea or nausea. By focusing on patient education, shared decision-making, and scheduled follow-up visits, they empower patients to better understand their condition and stay engaged in their care. This conversation provides practical guidance for both GI providers and patients navigating IBS-C management. For more educational resources, visit GHAPP.org and download the GHAPP ACE App.

#IBSC #IrritableBowelSyndrome #Gastroenterology #DigestiveHealth #GutHealth #GIHealth #IBSManagement #IBSConstipation #PatientEducation #GHAPPcast

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(154)

Medication Review: Guselkumab IV vs SC Formulation

Medication Review: Guselkumab IV vs SC Formulation

Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory...

28 Mai 3min

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

Thank you to Salix for the support on this FAQ Video Module.This educational FAQ module, featuring Mikhail Alper, PA-C focuses on recognizing risk factors and early clinical indicators of Overt Hepati...

26 Mai 2min

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

Thank you to Johnson & Johnson for the support on this FAQ Video Module.This FAQ video features Janette Villalon, PA, who reviews the role of guselkumab in treating extraintestinal manifestations in p...

19 Mai 5min

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the evolving role of monotherapy versus combination therapy in the treatment of inflammato...

14 Mai 3min

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the role of stable pharmacokinetics (PK) in achieving continuous inflammatory control in i...

7 Mai 6min

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Thank you to Johnson & Johnson for the support on this Journal Club Review Module.In this journal club video, Sharon Dudley Brown, CRNP, PhD, from the IBD Center at Johns Hopkins University, reviews t...

28 Apr 5min

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Thank you to AbbVie for the support on this Journal Club Review Module.This journal club review episode explores the benefit–risk profile of Upadacitinib for patients with moderately to severely activ...

21 Apr 23min

Podcast: How Do You Best Support Patients Getting Started on New MASH Treatments?

Podcast: How Do You Best Support Patients Getting Started on New MASH Treatments?

Learn how to effectively support patients starting treatment for MASH with this practical, clinician-focused discussion featuring expert advanced practice providers. In this episode, hepatology specia...

14 Apr 18min

Populært innen Helse

fastlegen
rss-gukild-johaug
lydartikler-fra-aftenposten
psykodrama
hvordan-har-du-det-mann
leger-om-livet
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
foreldreradet
rss-garne-damer
bak-fasaden-en-reise-i-livet-med-sykepleier-ine
rss-skravla-gar
morten-ramm-lar-kakla-ga-til-du-sovner
klimaks
rss-lopedrommen
hjernesterk
g-punktet
sinnsyn
hverdagspsyken
rss-kunsten-a-leve
apent-forhold